HOMA-PULSE: Assessment of Glucose Metabolism and Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation
Sponsor: Nemocnice AGEL Trinec-Podlesi a.s.
Trial Details
| Condition | Atrial Fibrillation, Insulin Resistance, Catheter Ablation, Artificial Intelligence |
| Status | Unknown |
| Participants | 120 |
| Est. Completion | 1 Dec 2028 |
| Last Updated | 27 Apr 2026 |
Primary Outcome
Rate of Reablation at 4-5 Months; Prevalence of Insulin Resistance in Non-Diabetic AF Patients Undergoing PFA; Association Between HOMA-IR and Reablation Risk
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Age \>= 18 years * Undergoing first catheter ablation for atrial fibrillation using pulsed field ablation (PFA) * No known diagnosis of diabetes mellitus * Signed written informed consent Exclusion Criteria: * Known diabetes mellitus or active antidiabetic treatment * Previous atrial fibrillation ablation by any method * Pregnancy * Severe renal insufficiency (eGFR \< 30 mL/min) * Other severe comorbidities limiting follow-up * Inability to provide informed consent
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service